Clinical Trials Browser

olaparib × Thoracic × 90 days × Clear all

Parkinson Disease 4, Autosomal Dominant Lewy Body, Small Cell Lung Carcinoma

NCT04380636 2026-05-15

MK-7339-012

Phase 3 Active not recruiting

870 enrolled

Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06217757 2026-05-05

Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC

Phase 1/2 Recruiting

45 enrolled

Thoracic

Lung Neoplasms, Small Cell Lung Carcinoma

NCT02498613 2026-05-01

A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors

Phase 2 Active not recruiting

122 enrolled 16 charts

BreastThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT03775486 2026-05-01

ORION

Phase 2 Active not recruiting

401 enrolled 26 charts

Thoracic

Non-small Cell Lung Cancer NSCLC

NCT02734004 2026-04-20

MEDIOLA

Phase 1/2 Active not recruiting

264 enrolled 32 charts

BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Small Cell Lung Carcinoma

NCT04375267 2026-04-14

LuPARP

Phase 1 Completed

18 enrolled

EndocrineNETOther solid neoplasmThoracic

Mesothelioma, Thymoma, Neuroendocrine Tumors

NCT06130254 2026-04-09

Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers

Phase 1 Terminated

1 enrolled

Other solid neoplasmThoracic

Advanced Solid Tumor

NCT02679963 2026-04-06

PIPSeN

Phase 2 Terminated

180 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03923270 2026-04-01

Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer

Phase 1 Active not recruiting

25 enrolled

Thoracic

Lung Neoplasms, Small Cell Lung Carcinoma

Clinical Trials

MK 7339-013

MK-7339-012

Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC

A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors

ORION

MEDIOLA

LuPARP

Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers

PIPSeN

Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer